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The antimicrobial susceptibility proﬁles of 76 Streptococcus agalactiae (Group B Streptococci [GBS]) isolates from vaginal
specimens of pregnant women near term were correlated to their genotypes generated by Random Ampliﬁed Polymorphic
DNA analysis and their virulence factors encoding genes cylE, lmb, scpB, rib,a n dbca by PCR. Based on the distribution of the
susceptibility patterns, six proﬁles were generated. RAPD analysis detected 7 clusters of genotypes. The cylE gene was present in
99% of the isolates, the lmb in 96%, scpBin 94.7%, ribin 33%, and bca in 56.5% of isolates. The isolates demonstrated a signiﬁcant
correlation between antimicrobial resistance and genotype clusters denoting the distribution of particular clones with diﬀerent
antimicrobial resistance proﬁles, entailing the practice of caution in therapeutic options. All virulence factors encoding genes were
detected in all seven genotypic clusters with rib and bca not coexisting in the same genome.
Copyright © 2009 Antoine Hannoun et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Neonatal group B streptococcus (GBS) infection ranging
from 0.5 to 2 per 1000 live birth is the result of vertical
transmission to the infant during delivery in colonized
mothers[1].AttemptsatidentifyingGBScolonizedpregnant
women near term by assessing the risk factors for GBS,
failed to diagnose all cases [2]. Universal screening of all
pregnant women for GBS at 35–37 weeks of gestation is
currently recommended by the Centers for Disease Control
and Prevention (CDC) in the USA [2].
Despite the variation in the adherence to CDC rec-
ommendations among diﬀerent centers around the world,
antimicrobial prophylaxis, oﬀered to women colonized with
GBS intrapartum (after onset of labor or after rupture of
m e m b r a n e s ) ,l e a dt om o r et h a n7 0 %r e d u c t i o ni ne a r l y -
onset GBS infection in neonates [3]. However, due to the
variation in the rate of GBS colonization during pregnancy
[4], the emergence of resistant colonizing strains [5] and the
virulence potential of these strains, intrapartum screening of
GBS genotypes [6] along with their antimicrobial resistance
proﬁles, and virulence encoding genes become desirable.
Fortunately, GBS resistance to penicillin has not been
reported so far [7]; however, rare GBS clinical strains with
reduced sensitivity for penicillin have been recorded [8]. On
the other hand, early studies on GBS isolates from pregnant
women, showed antimicrobial resistance as high as 18%, 8%,
and >80% for erythromycin, clindamycin, and tetracycline
respectively [9].
The severity of neonatal disease in GBS infections could
be determined mostly by a number of virulence factors
encoded among others by the cps gene cluster coding for
the capsule [10], the scpB gene coding for surface enzyme
ScpB(aC5apeptidase)whichcausesimpairingofneutrophil2 International Journal of Microbiology
recruitment and binds ﬁbronectin to promote bacterial
invasion of epithelial cells [11], the bca gene coding for
alpha-C protein, a surface protein that helps the bacteria
to enter the host cells [12], the lmb gene coding for lmb
(laminine-binding protein), a surface protein that plays
a role in invasion of damaged epithelium [13], the cylE
gene coding for β-hemolysin, a toxin that plays a role
in tissue injury and systemic spread of the bacteria and
contributes to meningitis [14], and the rib gene encoding
the surface Rib protein mostly present in invasive strains
[15]. Other virulence factors involved in the process of
GBS pathogenesis include beta-C protein which is encoded
by bac gene. Beta-C protein function is comprised of
interaction with IgA-Fc portion causing the inhibition of
phagocytosis [16] and binding Factor-H to maintain its role
in inhibiting the complement activation via the alternative
pathway [17]. Other important virulence factors of GBS
are the Fibrinogen-Binding proteins: FbsA and FbsB. FbsA
is a surface protein encoded by fbsA gene. It protects the
pathogenfromopsonophagocytosis,andpromotesitsadher-
ence to epithelial cells and to the human brain microvascular
endothelial cells (HBMEC) thus helping it to cross the
blood brain barrier and developing meningitis [18, 19]. FbsB
protein, encoded by fbsB gene, is also a surface protein that
helps in GBS invasion of the epithelial cells [20]. Finally,
cell-surface-associated protein (CspA) is a surface protein
encoded by cspA gene. It is involved in maintaining the
pathogensurvivalinthehostbyescapingtheimmunesystem
[21].
In this study, genotypes were correlated to some of the
virulence genes and the antimicrobial susceptibility proﬁles.
This information is useful to identify particular GBS strains
with high virulence potential, with resistance to routinely
administered antimicrobial agents, and possibly linked to
particular geographical areas.
2.MaterialsandMethods
2.1. Bacterial Isolates. S e v e n t ys i xG B Si s o l a t e sw e r ec u l t u r e d
from specimen taken from the vaginas of pregnant women
between 35 and 37 weeks of gestation, attending private
clinics in two tertiary care centers in Beirut, Lebanon,
between October 2007 and July 2008. The ﬁrst center (A)
is located in the western part of the urban city of Beirut,
and the second one (B) in the eastern part of Beirut. These
two hospitals serve two diﬀerent populations, in the sense
that patients attending the hospitals come from 2 diﬀer-
ent geographical areas, with very minimal intermingling
between them. However, the local health care systems of the
two areas are similar, and patients have similar antibiotics
consumption habits. The 76GBS isolates consisted of 47
(61.8%) isolates obtained from the ﬁrst tertiary care center
and 29 (38.2%) isolates obtained from the second tertiary
care center.
2.2. Identiﬁcation. Isolates were identiﬁed using conven-
tional methods on the basis of colonial morphology, Gram
staining, haemolysis, and latex agglutination test with spe-
ciﬁc antisera using the Slidex Strepto Plus (BioMerieux,
Marcy L’Etoile; France).
2.3. Antimicrobial Susceptibility Testing. Antimicrobial sus-
ceptibility testing was performed by the disk-diﬀusion
(Kirby-Bauer) method on Mueller-Hinton agar (Difco Lab-
oratories, Detroit, Michigan) supplemented with 5% sheep
blood, using suspensions of 0.5 MacFarland from fresh
bacterial cultures. The test was done using the follow-
ing antimicrobial agents: penicillin, cefepime, ceftriaxone,
chloramphenicol, clindamycin, erythromycin, levoﬂoxacin,
and tetracycline. Results were interpreted according to the
Clinical Laboratory Standard Institute (CLSI) [22].
2.4. Total DNA Extraction. DNA was extracted from all
isolates using the illustra bacteria genomicPrep Mini Spin
Kit (GE Healthcare UK Ltd, Buckinghamshire, England)
according to the manufacturer’s instructions.
2.5. Polymerase Chain Reaction (PCR). Total DNA of the
76GBS isolates was used to amplify ﬁve virulence factors
encoding genes: cylE [23], rib [24], lmb [25], bca [25], and
scpB [26] by PCR using speciﬁc primers. Standard PCR
conditions were used to amplify cylE, lmb,a n dscpB [23], rib
[24], and bca gene [25].
PCR reactions were performed in the Sprint, Thermo
Electric thermal cycler. Amplicons were subjected to elec-
trophoresis on 2% agarose (Sigma) gels in 1 × Tris-Borate-
EDTA buﬀer pH 8.3 (Tris base 0.089M, Boric acid 0.089M,
and EDTA 0.002M) at 120V for 45 minutes.
Agarose gels were stained with ethidium bromide
(Sigma) and photographed using a UV-transilluminator and
an Olympus digital camera with Digi-Doc it Program.
2.6.Genotyping. GenotypingusingRandomAmpliﬁedPoly-
morphic DNA (RAPD) analysis was performed on all the
isolates to determine strain diversity. RAPD was performed
with the Ready-To-Go RAPD Analysis Beads kit (GE Health-
care UK Ltd, Buckinghamshire, England) and the GBS 2
primer [6], using Sprint, Thermo Electric thermal cycler. A
dendrogram was generated for the RAPD patterns using the
BIONUMERICS software. (Applied Maths, Saint-Martens-
Latem, Belgium.)
3. Results
3.1. Bacterial Isolates Distribution and Antimicrobial Sus-
ceptibility. Antimicrobial susceptibility testing showed the
following: all GBS isolates were susceptible to penicillin
G, cefepime, ceftriaxone, and levoﬂoxacin. The following
percentages of isolates, 4%, 11.8%, 15.8%, and 86.8%, were
resistant to chloramphenicol (CHL), clindamycin (CLI),
erythromycin (ERY), and tetracycline (TET) respectively.
Six antimicrobial resistance (AR) proﬁles of isolates were
detected: A (resistant to CLI, ERY, CHL, and TET; 4.0%),
B (resistant to CLI, ERY, and TET; 6.6%), C (resistant to
CLI and TET; 1.3%), D (resistant to ERY and TET; 5.3%),International Journal of Microbiology 3
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Figure 1: Dendrogram of the random ampliﬁed polymorphic DNA (RAPD) analysis of all GBS isolates.
E (resistant to only TET; 69.7%), and F (susceptible to all;
13.2%).
3.2. RAPD Analysis. Genotyping of all the isolates detected
seven GBS clusters I, II, III, IV, V, VI, and VII with the
following prevalence percentages: 18.4%, 13.2%, 19.4%,
7.9%, 11.8%, 11.8%, and 17.1%, respectively. A dendrogram
of the seven clusters of genotypes is shown in Figure 1.T h e
most common cluster was III (19.7%) and the least prevalent
was IV (7.9%). Table 1 shows the correlation between GBS
clusters and their AR proﬁles.
The data show a prevalence of certain genotype clusters
in both tertiary care centers while other genotype clusters
were merely conﬁned to a particular tertiary center (Table 2).
Similarly, certain AR proﬁles were prevalent in both centers,
whereas others were restricted to one center.
3.3. PCR Ampliﬁcation of the Virulence Genes. PCR detection
of the virulence genes showed that cylE, lmb, scpB, bca,
and rib genes were positive in 99%, 96.1%, 94.7%, 56.6%,
and 33% of the GBS isolates respectively. There was a wide
prevalence of the cylE, lmb,a n dscpB genes among the total4 International Journal of Microbiology
Table 1: Distribution of antimicrobial resistance proﬁles among GBS genotype clusters.
AR proﬁle (# of isolates) A (3) B (5) C (1) D (4) E (53) F (10)
Genotype Clusters (# of isolates)
I (14) 0 2 0 1 8 3
II (10) 0 1 0 0 9 0
III (15) 0 0 1 0 13 1
IV (6) 0 0 0 0 3 3
V( 9 ) 1 0 0 2 6 0
VI (9) 1 0 0 1 5 2
VII (13) 1 2 0 0 9 1
Antimicrobial Resistance (AR) proﬁle: resistance to CLI, ERY, CHL, and TET (A); resistance to CLI, ERY, and TET (B); resistance to CLI and TET (C);
resistance to ERY and TET (D); resistance to only TET (E); susceptible to all antibiotics (F).
Table 2: Distribution of GBS genotypes in two medical centers.
Medical Center A (49) B (27)
Genotype Clusters (# of isolates)
I (14) 7 7
II (10) 10 0
III (15) 0 15
IV (6) 6 0
V( 9 ) 9 0
VI (9) 4 5
VII (13) 13 0
A: Medical center located in the Western part of Beirut.
B: Medical center located in the Eastern part of Beirut
Table 3: Distribution of bca and rib virulence genes in GBS
genotype clusters.
Genotype Clusters bca gene rib gene
(# of isolates) # positive (%) # positive (%)
I (14) 5 (35.7) 6 (42.9)
II (10) 6 (60.0) 4 (40.0)
III (15) 9 (60.0) 5 (33.3)
IV (6) 5 (83.3) 1 (16.7)
V (9) 4 (44.4) 3 (33.3)
VI (9) 7 (77.8) 2 (22.2)
VII (13) 7 (53.8) 4 (30.7)
Total (76) 43 (56.5) 25 (32.9)
isolates, and hence all 3 genes were evenly distributed among
the genotype clusters. Table 3 shows the prevalence of bca
and rib genes among the GBS genotype clusters. Sixty eight
isolates out of 76 (89.5%) have either the bca or the rib gene
and 8 isolates out of 76 (10.5%) have neither bca nor rib
detected.
4. Discussion
Neonatal GBS infection is a serious complication of the
vertical transmission of the bacteria, from the mother to the
newborn, at the time of vaginal delivery [1]. This is why
universal screening for GBS vaginal colonization in pregnant
women near term is recommended [2].
Fortunately, GBS resistant to penicillin has not been
reported all around the world, and the drug of choice, in
treating the infection, is still penicillin [7, 9]. However, the
problem arises in cases, allergic to penicillin, where alternate
antimicrobial agents such as CLI and ERY are commonly
administered [2]. However, De Azavedo et al. [9] found that
18%, 8%, and >80% of GBS isolates in pregnant women
were resistant to ERY, CLI, and TET [9]. In our study, 11.8%,
15.8%, and 86.8% of the GBS isolates, were resistant to ERY,
CLI, and TET respectively, indicating percentages similar
to previous studies. The prevalence of this relatively high
AR percentages, leads to the recommendation of requesting
a sensitivity antibiogram for GBS cultured from women
allergic to penicillin.
Genotyping of all the GBS isolates, utilizing RAPD
analysis determined a total of 7 genotype clusters. The most
common was genotype cluster III (19.7%) and the least
common was IV found in 7.9% of all isolates.
A correlation between AR and genotype clusters, showed
an association between them (Table 1). Resistance to CHL
was restricted to genotype clusters V, VI, and VII, whereas
resistance to both CLI and ERY was found only in genotype
clusters I, II, and VII. All the GBS isolates resistant to CLI are
also resistant to ERY, indicating a correlating pattern of resis-
tance amongst the genes responsible for this phenotype. This
can be expected since CLI resistance in GBS is nearly always
based on the presence of an ermB gene conferring resistance
to macrolides, lincosamides, and streptogramin B [27].
An important ﬁnding in this study was the correlation
between the prevalence of particular genotype clusters with
certain AR proﬁles in a given medical center. This observa-
tiondenotesthathighprevalenceofcertaingenotypeclusters
resistant to certain antimicrobial agents in a particular med-
ical center entails the practice of caution by extrapolating the
AR ﬁndings from one medical center to others.
Another observation is that bca and rib g e n e sw e r en o t
present concomitantly in the same genome. Previous studies
noted this observation [28, 29]. Rib protein encoded by the
rib gene shares several properties with α-C protein encoded
by bca gene. Both proteins are resistant to trypsin digestion
and belong to the same family of bacterial surface proteinsInternational Journal of Microbiology 5
with repetitive structures showing a 47% identity, their N-
terminal sequences are related and are 61% identical to
each other [30]. These properties suggest that both proteins
may have a common origin. Further investigations are still
needed to be performed in order to discover the functional
relationship between bca and rib to determine if they have
homologous functions.
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